# COU-AA-301 (NCT00638690)

> Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

No report yet. It can be ordered.

- Drugs tested: abiraterone
- Indication: metastatic castration-resistant prostate cancer after docetaxel

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00638690
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Cougar Biotechnology, Inc.
- Conditions: Prostatic Neoplasms
- Interventions: Placebo; Abiraterone acetate; Prednisone/prednisolone
- Enrollment: 1195
- Primary outcome: Overall Survival

## Indexed commentary on COU-AA-301 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 5 posts on X
- 3 podcast episodes

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=cou-aa-301-nct00638690

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00638690", "email": "<work email>"}; the inbox owner confirms by the emailed link.